COBITOLIMOD FOR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

The present invention provides an oligonucleotide comprising the sequence 5'-GGAACAGTTCGTCCATGGC-3' (SEQ ID NO:2) for use in the treatment of inflammatory bowel disease in a human subject, wherein individual doses of from 150mg to 350mg of said oligonucleotide are administered to the subje...

Full description

Saved in:
Bibliographic Details
Main Authors SANDWALL PERNILLA, KNITTEL THOMAS, ADMYRE CHARLOTTE, ZARGARI AREZOU, ZERHOUNI PETER
Format Patent
LanguageChinese
English
Published 10.01.2020
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides an oligonucleotide comprising the sequence 5'-GGAACAGTTCGTCCATGGC-3' (SEQ ID NO:2) for use in the treatment of inflammatory bowel disease in a human subject, wherein individual doses of from 150mg to 350mg of said oligonucleotide are administered to the subject on at least two separate occasions, wherein said separate occasions are 3 weeks apart. 本发明提供了包含序列5'-GGAACAGTTCGTCCATGGC-3'(SEQ ID NO:2)的寡核苷酸在治疗人类受试者的炎症性肠病中的应用，其中在至少两次分开的场合下，向受试者给药单次剂量为150mg至350mg的所述寡核苷酸，其中所述分开的场合相隔3周。
Bibliography:Application Number: CN201880031203